TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01129570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silybin
Description: 4 dose levels of siliphos: 2, 4, 8, and 12 grams daily in three divided doses. This study will follow a standard sequential Phase I dose escalation design.
Study: NCT03005171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Thoracic epidural bupivacaine infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Intravenous lidocaine infusion
Study: NCT01949285

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Spinal Cord Stimulation
Description: A prototype device that non-invasively delivers electrical stimulation to the spinal cord will be used to assess and rehabilitate spared spinal cord function.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous Electrical Spinal Cord Stimulation
Description: A prototype device that non-invasively delivers electrical stimulation to the spinal cord will be used to assess and rehabilitate spared spinal cord function.
Study: NCT00782327

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: Daily maximal doses of Losartan will be 50mg for subjects under 50kg of weight and 100mg if the weight is over 50kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo capsule
Study: NCT01982331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LAIV H2N2
Description: vaccine is delivered intranasally, .25 cc to each nostril at day 0 and day 28

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo delivered intranasally. .25cc to each nostril at day 0 and day 28
Study: NCT03506867

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life skills, training, education and work/volunteer opportunities
Description: Intervention arm will receive proactive and sustained access to enhanced education and socio-economic supports (e.g. volunteer and/or work opportunities).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Usual care will receive information on locally available services.
Study: NCT02772679

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PolyTregs+IL-2
Description: PolyTregs will be infused into the patient in a single infusion. The first cohort will receive 3 x10\^6 cells. The second cohort will receive 20x10\^6 cells. Following the day 0 infusion of polyclonal Tregs, subjects will receive two 5-day courses of IL-2 (1 x 106 IU daily), the first on days 3-7 and the second on days 38-42. Administration of the second course of IL-2 may be delayed or withheld depending on threshold criteria for peripheral blood Treg frequencies and MMTT-stimulated C-peptide levels determined on day 28.
Study: NCT03967678

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Three portions per week (690g beef (raw weight)) for 5 weeks
Description: Lunches served in Human Intervention Studies Unit

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Three portions per week (690g beef (raw weight)) for 5 weeks
Description: Lunches served in Human Intervention Studies Unit

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Three portions per week (690g beef (raw weight)) for 5 weeks
Description: Lunches served in Human Intervention Studies Unit
Study: NCT05348135

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: functional strength training
Description: children in this group received FST. Each training session started with 10 minutes dynamic warm-up period and ended with 5 minutes cool down in the form of muscle stretching and aerobics. The warm up was followed by gait training in addition to 4 functional lower limb exercises; sit to stand exercise, forward/ lateral step-up exercise, half knee rise exercise, and bridging exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: functional strength training
Description: children in this group received FST. Each training session started with 10 minutes dynamic warm-up period and ended with 5 minutes cool down in the form of muscle stretching and aerobics. The warm up was followed by gait training in addition to 4 functional lower limb exercises; sit to stand exercise, forward/ lateral step-up exercise, half knee rise exercise, and bridging exercise.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training
Description: Children in this group received cognitive training by RehaCom cognitive rehabilitation software. Training was applied for four cognitive domains of function; attention / concentration, figural memory, reaction behavior and logical reasoning.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cognitive training
Description: Children in this group received cognitive training by RehaCom cognitive rehabilitation software. Training was applied for four cognitive domains of function; attention / concentration, figural memory, reaction behavior and logical reasoning.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional physical therapy
Description: including reinforcement of normal motor development, reflex inhibiting patterns, balance exercises, stretching exercises and gait training
Study: NCT03732833

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be injected into either the GL, or both the LCL and GL.
Study: NCT01876758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Intervention: Memory Training
Description: Paper-and-pencil and computerized exercises pre- and post-ECT which may be helpful in recovering episodic memories and allow for the retention of learned strategies

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparable general mental stimulation
Description: Active control will work on commercially available puzzle games at the same time prior and after ECT to determine if the developed memory training program is more effective than mere mental stimulation.
Study: NCT02405793

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Test Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Test Capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meloxicam Tablets
Study: NCT01972919

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Radiation therapy dose escalation to an MR-defined gross tumor volume (GTV) of up to 69.75 Gy at 2.25 Gy per fraction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concurrent chemotherapy (Gemcitabine, Capecitabine)
Description: Gemcitabine 400mg/m\^2 IV weekly x 6 doses. Capecitabine 825 mg/m\^2 by mouth twice daily Monday-Friday on days of radiation use 500 mg tablets.
Study: NCT06549868

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Yoga-based bedtime routine
Description: Dyads in the yoga intervention group receive a picture book outlining a bedtime-themed yoga routine and are instructed to incorporate it into their bedtime routine at least four nights per week for four weeks. The routine guides children through a sequence of yoga poses, starting with the mountain pose and ending in child's pose, designed to calm them as the story progresses. Parents are given a bedtime diary to record the date, whether the child completed the yoga routine each evening, and any comments about their experience with the book.~At week 6, families return to the lab, complete anthropometric assessments and questionnaires, and are fitted with accelerometers to wear for the next week. The accelerometers are returned and data is downloaded a week later. Families are then encouraged to continue using the yoga routine as often as they wish for an additional four weeks, although the frequency of use is not tracked during this maintenance period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga-based bedtime routine
Description: Dyads in the yoga intervention group receive a picture book outlining a bedtime-themed yoga routine and are instructed to incorporate it into their bedtime routine at least four nights per week for four weeks. The routine guides children through a sequence of yoga poses, starting with the mountain pose and ending in child's pose, designed to calm them as the story progresses. Parents are given a bedtime diary to record the date, whether the child completed the yoga routine each evening, and any comments about their experience with the book.~At week 6, families return to the lab, complete anthropometric assessments and questionnaires, and are fitted with accelerometers to wear for the next week. The accelerometers are returned and data is downloaded a week later. Families are then encouraged to continue using the yoga routine as often as they wish for an additional four weeks, although the frequency of use is not tracked during this maintenance period.
Study: NCT02634697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Response Resiliency Program
Description: 8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Relaxation Response Resiliency Program
Description: 8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga
Study: NCT02524899

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Remediation Therapy
Description: Cognitive Remediation Therapy (CRT) will consist of fifteen 45-minute, twice weekly sessions over 7.5 weeks. During each session, subjects, seated at a desk in a private interview room in our research office suite, will work through exercises that are part of the Psychological Software Services CogReHab program. The software to be used is a multimedia, Windows-based program that consists of exercises aimed at improving areas of deficit within the schizophrenia spectrum, such as executive function, working memory, and social cognition.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Remediation Therapy
Description: Cognitive Remediation Therapy (CRT) will consist of fifteen 45-minute, twice weekly sessions over 7.5 weeks. During each session, subjects, seated at a desk in a private interview room in our research office suite, will work through exercises that are part of the Psychological Software Services CogReHab program. The software to be used is a multimedia, Windows-based program that consists of exercises aimed at improving areas of deficit within the schizophrenia spectrum, such as executive function, working memory, and social cognition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in the active treatment arm will begin with a guanfacine dose of 0.5mg/day and be titrated up to a maximum of 2mg/day according to our well-tolerated protocol in schizophrenia subjects. The dosing schedule of active guanfacine will be as follows: 0.5mg/d for week 1, 1.0mg/d for week 2, 1.0 mg bid for weeks 3, 4, 5, 6, and 7 and 1.0mg/d for week 8.
Study: NCT02644525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: A single dose of imatinib 200mg PO is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: A single dose of imatinib 400mg PO is given

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate
Description: A single dose of imatinib 600mg PO is given

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo pill is given
Study: NCT05272163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stimulus Type
Description: Targets can be specific or categorical

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Target Presence
Description: There is or is not a target present on each trial
Study: NCT03697226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical ABI-1968
Description: Multiple Doses of Topical ABI-1968 Cream with 4 once weekly doses administered in up to 5 Cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical ABI-1968
Description: Multiple Doses of Topical ABI-1968 Cream with 4 once weekly doses administered in up to 5 Cohorts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical ABI-1968
Description: Multiple Doses of Topical ABI-1968 Cream with 4 once weekly doses administered in up to 5 Cohorts
Study: NCT00515164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel
Description: 20 mL Hydrogel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel
Description: 20 mL Hydrogel
Study: NCT02162732

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Guided Therapy
Description: A total of 200 neuroblastoma, brain tumor, and rare tumor patients will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
Study: NCT01438229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)
Description: Catheter-based RF ablation in renal artery
Study: NCT04265547

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Cancer Risk Reduction Household Intervention
Description: This study will focus the intervention on ways at the individual level to reduce sources of Polycyclic Aromatic Hydrocarbons (through cooking methods, exposure to cigarette smoking, indoor air filters) and also individual ways to reduce sources of other Endocrine Disrupting Chemicals. Mother-daughter pairs will partake in an educational session at the baseline visit, covering topics on reading labels, cleaning habits, and cooking methods for reducing exposures. Participants will also be introduced to free resources for consumer product safety information. The intervention arm will receive a 6-month supply of soap, lotion, deodorant, lip balm, a mop, cleaning cloths, and an air filter to take home with them. Pairs in both study arms will return for a second clinic visit 6 months after the pre-intervention visit for blood and urine sample collection, Optical Spectroscopy measurement, and questionnaire completion. The control arm will be offered the intervention products at this time.
Study: NCT00429702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decadron®
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decadron®
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benadryl®
Description: Given IV
Study: NCT05272163

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Checklist
Description: In fact, there is a checklist on every trial but these results will be compared to a non-checklist condition from another experiment
Study: NCT01915849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 15 mg, 50 mg and 150 mg
Study: NCT00429702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ativan®
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ondansetron hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron hydrochloride
Description: Given IV
Study: NCT02424461

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: 1 injection 1 g per day for 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone
Description: 1 injection 1 g per day for 2 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacine
Description: 400 mg/jour (200 mg/ jour in case of renal failure) for seven days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacine
Description: 400 mg/jour (200 mg/ jour in case of renal failure) for seven days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ofloxacine
Description: 400 mg/jour (200 mg/ jour in case of renal failure) for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of ofloxacine
Description: Placebo of ofloxacine for 7 days
Study: NCT03377075

Intervention type: DEVICE
Intervention: AL measurement
Description: IOL Master 500 (Carl Zeiss AG, Germany)

Intervention type: DEVICE
Intervention: OCT
Description: Choroidal and retinal thickness measurement (DRI OCT-1 Model Triton (plus), Topcon, Tokyo, Japan)
Study: NCT04055896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medication Reduction
Description: Systematic approach to reduction in polypharmacy
Study: NCT02181205

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study: NCT01915849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 15 mg, 50 mg and 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 15 mg, 50 mg and 150 mg
Study: NCT02859597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: High flow nasal cannula at 50 liters per minute and 50% oxygen will initially be used for oxygenation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Cannula
Description: Control group will receive oxygen via standard flow nasal cannula at 5 liters per minute (approximately an FiO2 of 0.35)
Study: NCT01253980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin syrup 20-30mg/kg 8 hourly for 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo suspension made of water, dextrose and glycerine with a similar taste and appearance to the active comparator.~Dose 20-30mg/kg 8 hourly for 5 days
Study: NCT00447915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibandronic acid 0.5mg
Description: 0.5mg(i.v.)/month for 35 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIS placebo
Description: 0 mg(p.o.)/day for 36 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RIS placebo
Description: 0 mg(p.o.)/day for 36 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1.0mg ibandronic acid
Description: 1.0mg(i.v.)/month for 35 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ibandronic acid placebo
Description: 0mg(i.v.)/month for 35 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2.5mg RIS
Description: 2.5 mg(p.o.)/day for 36 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamine D3
Description: Calcium 305 mg and Vitamine D3 200IU(p.o.)/day for 36 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Calcium and Vitamine D3
Description: Calcium 305 mg and Vitamine D3 200IU(p.o.)/day for 36 months
Study: NCT02524899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in placebo arm will have matching schedule as active arm.
Study: NCT02124005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Study: NCT00447915

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and Vitamine D3
Description: Calcium 305 mg and Vitamine D3 200IU(p.o.)/day for 36 months
Study: NCT01915849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 15 mg, 50 mg and 150 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02280681

Intervention type: OTHER
Intervention: No intervention, only questionnaire
Description: No intervention, only questionnaire containing a discrete choice experiment identifying the importance of treatment aspects for deciding between current treatments and possible future treatments with artificial gametes

Intervention type: OTHER
Intervention: No intervention, only questionnaire
Description: No intervention, only questionnaire containing a discrete choice experiment identifying the importance of treatment aspects for deciding between current treatments and possible future treatments with artificial gametes
Study: NCT03819244

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 940 nm Gallium Aluminum Arsenide Diode Laser
Description: Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with diode laser for placing the healing abutment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2780 nm Er,Cr:YSGG Laser
Description: Exposure of the cover screw of osseointegrated dental implants embedded under oral mucosa by performing the soft tissue incision with erbium laser for placing the healing abutment.
Study: NCT01489787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIFU
Description: The shootings will concern the healthy liver to remove, distant to the important vascular structures and metastases. Two HIFU shootings will be made on each patient:~* One hurt on the surface starting from the Glisson capsule and extending to subjacent hepatic parenchyma.~* One hurt at given depth, at least 10 mm deeper than the hurt done on the surface NB: The shooting depth will determined for each patient at the beginning of the operation, considering preoperative exams (scans, etc.), size and location of the liver part to be resected and physical structure of the patient.
Study: NCT02336633

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: 2 capsules of 20mg in the morning and in the evening (4 capsules in total/day = 80mg/day) every day during 1 year

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo